| Logo | Name | Σ | ||
|---|---|---|---|---|
 | Entrepreneur First Entrepreneur First invests in exceptional individuals to build startups from scratch. Entrepreneur First invests in exceptional individuals to build startups from scratch. We bring together talented outliers to develop their most ambitious ideas and raise money from the world’s best investors. Since pioneering Talent Investing in 2014, we’ve learned to recognize individuals with extraordinary futures before anyone else, embedding them in a community of ambitious peers and giving them the tools they need to succeed, fast. We back them before they have a company, a team, even before they have an idea, based purely on talent. The startups cofounded on … Sectors: | 606 | 426 | 135 |
 | La French Tech Paris-Saclay Une capitale French Tech à l'écoute des start-up deeptech de Paris-Saclay « La French Tech » : c’est le mouvement français des startups. Un écosystème unique qui réunit des startups (donc), mais aussi des investisseurs, des décideurs et des community builders. La French Tech Paris-Saclay Capitale labélisée en IdF au côté de la capitale French Tech Grand Paris. Sectors: | 411 | 155 | 300 |
 | HEC Paris Specialized in education and research in management, HEC Paris Business School offers a complete and unique range of educational programs for the leaders of tomorrow: Masters Programs, MBA, PhD, HEC Executive MBA, TRIUM Global Executive MBA and Executive Education open-enrolment and custom programs. Founded in 1881 by the Paris Chamber of Commerce and Industry and founding member of ParisTech, HEC Paris has a permanent faculty of 115 professors, more than 4,000 students and over 8,500 managers and executives in training every year. management, corporate governance, strategy, general management, finance, human resources, marketing, operations management, entrepreneurship, coaching, business, business school, executive, … | 1995 | 751 | 1203 |
 | Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO. Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins, … Sectors: | 381 | 328 | 55 |
 | WILCO [Automatic translation follows] Liberator of ambitions that helps women and men realize their innovative transformation projects. Challenger. Disrupter. Transform Create economic value. Positively impact society. This is what drives the WILCO teams. startups, honor loan, innovation, fundraising, Open Innovation, FrenchTech, Digital, Healthcare, Industry, Health, Fundraising, Acceleration, ETI, Large Groups, Corporate, and Intrapreneurship | 618 | 146 | 538 |
 | Hello Tomorrow Building a collaborative ecosystem that leverages the power of deep technologies to tackle world challenges. Hello Tomorrow was created in 2011 by a group of individuals convinced that science and technology need to form part of a toolkit of solutions to change our industries, sustain a growing population and help solve global crises. But the traditional model of technology transfer to bring solutions from lab to market, and from idea to impact, could not rise to this challenge. In turn, Hello Tomorrow has built, and now animates, a global ecosystem that facilitates ‘deep tech’ innovation through multiple activities. Over the … Sectors: | 506 | 331 | 199 |
 | SATT Paris-Saclay [Automatic translation follows] Innovation with confidence Created in 2014 and resulting from the "Investments for the Future" Program, SATT Paris-Saclay is the Technology Transfer Acceleration Company of the Paris-Saclay Cluster. A common player for both entities - Université Paris-Saclay and Institut Polytechnique de Paris - SATT has an investment capacity of 66 million euros over 10 years to finance and support the development of research work from the region and technology transfer to markets. Innovation, Technology Transfer, and Start-up Tags: SATT Network Sectors: | 227 | 107 | 147 |
 | Genopole Genopole, biocluster leader en France, Vivre l'innovation Created in 1998, Genopole® has a threefold mission: - develop a high-level research campus in genomics and post-genomics, focused on gene therapy in collaboration with the University Evry-Paris Saclay, - encourage the start-up and foster the development of biotech companies in the Paris region by providing personalized advice and support, including financial assistance - create a biopark in Evry-Courcouronnes in collaboration with the research campus. biocluster, research campus - academical laboratories, biotech companies, university, life sciences companies, Infrastructure - Shared-use technology platforms, and Biotherapy Sectors: | 304 | 157 | 157 |
 | CEA The CEA is the French Alternative Energies and Atomic Energy Commission ("Commissariat à l'énergie atomique et aux énergies alternatives"). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and … Sectors: | 2632 | 1681 | 316 |
 | Novo Nordisk Driving change to defeat serious chronic diseases, built upon our heritage in diabetes. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments … Sectors: | 1336 | 1089 | 144 |
Startup accelerator & VC